99 related articles for article (PubMed ID: 30272249)
21. Nicotine Promotes WRL68 Cells Proliferation Due to the Mutant p53 Gain-of-Function by Activating CDK6-p53-RS-PIN1-STAT1 Signaling Pathway.
Wang H; Chen L; Zhou T; Zhang Z; Zeng C
Chem Res Toxicol; 2020 Sep; 33(9):2361-2373. PubMed ID: 32820905
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
Huang K; Tang Y; He L; Dai Y
Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
[TBL] [Abstract][Full Text] [Related]
23. Expression of cellular genes in HPV16-immortalized and cigarette smoke condensate-transformed human endocervical cells.
Yang X; Nakao Y; Pater MM; Tang SC; Pater A
J Cell Biochem; 1997 Sep; 66(3):309-21. PubMed ID: 9257188
[TBL] [Abstract][Full Text] [Related]
24. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
Goodwin EC; DiMaio D
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12513-8. PubMed ID: 11070078
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
de Stephanis L; Mangolini A; Servello M; Harris PC; Dell'Atti L; Pinton P; Aguiari G
J Cell Physiol; 2018 Sep; 233(9):6911-6924. PubMed ID: 29323708
[TBL] [Abstract][Full Text] [Related]
26. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.
Raza S; Ohm JE; Dhasarathy A; Schommer J; Roche C; Hammer KD; Ghribi O
Mol Cell Biochem; 2015 Dec; 410(1-2):187-95. PubMed ID: 26350565
[TBL] [Abstract][Full Text] [Related]
27. Regulation of the MDM2-p53 pathway by the nucleolar protein CSIG in response to nucleolar stress.
Xie N; Ma L; Zhu F; Zhao W; Tian F; Yuan F; Fu J; Huang D; Lv C; Tong T
Sci Rep; 2016 Nov; 6():36171. PubMed ID: 27811966
[TBL] [Abstract][Full Text] [Related]
28. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells.
Bhattacharya S; Ray RM; Johnson LR
Cell Signal; 2009 Apr; 21(4):509-22. PubMed ID: 19136059
[TBL] [Abstract][Full Text] [Related]
29. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
Camus S; Higgins M; Lane DP; Lain S
FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
31. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
32. RP-MDM2-p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance.
Liu Y; Deisenroth C; Zhang Y
Trends Cancer; 2016 Apr; 2(4):191-204. PubMed ID: 28741571
[TBL] [Abstract][Full Text] [Related]
33. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
34. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
35. The Evolution of the Ribosomal Protein-MDM2-p53 Pathway.
Deisenroth C; Franklin DA; Zhang Y
Cold Spring Harb Perspect Med; 2016 Dec; 6(12):. PubMed ID: 27908926
[TBL] [Abstract][Full Text] [Related]
36. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Kundu N; Brekman A; Kim JY; Xiao G; Gao C; Bargonetti J
Oncotarget; 2017 Jul; 8(29):47916-47930. PubMed ID: 28615518
[TBL] [Abstract][Full Text] [Related]
37. SHARPIN Facilitates p53 Degradation in Breast Cancer Cells.
Yang H; Yu S; Wang W; Li X; Hou Y; Liu Z; Shi Y; Mu K; Niu G; Xu J; Wang H; Zhu J; Zhuang T
Neoplasia; 2017 Feb; 19(2):84-92. PubMed ID: 28063307
[TBL] [Abstract][Full Text] [Related]
38. Lipopolysaccharide Affects the Proliferation and Glucose Metabolism of Cervical Cancer Cells Through the FRA1/MDM2/p53 Pathway.
Jiang X; Yuan J; Dou Y; Zeng D; Xiao S
Int J Med Sci; 2021; 18(4):1030-1038. PubMed ID: 33456361
[TBL] [Abstract][Full Text] [Related]
39. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
40. Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis.
Liu S; Tackmann NR; Yang J; Zhang Y
Oncogene; 2017 Mar; 36(10):1374-1383. PubMed ID: 27617574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
